Flolipid is owned by Tcg Fluent Pharma.
Flolipid contains Simvastatin.
Flolipid has a total of 2 drug patents out of which 0 drug patents have expired.
Flolipid was authorised for market use on 21 April, 2016.
Flolipid is available in suspension;oral dosage forms.
The generics of Flolipid are possible to be released after 23 February, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10300041||TCG FLUENT PHARMA||Liquid oral simvastatin compositions|| |
(3 years from now)
|US9597289||TCG FLUENT PHARMA||Liquid oral simvastatin compositions|| |
(6 years from now)
Drugs and Companies using SIMVASTATIN ingredient
Market Authorisation Date: 21 April, 2016
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic